Skip to main content

Compaq Seals Equipment Deal with Entelos

NEW YORK, Aug. 15 – Compaq has inked a three-year deal with biosimulation company Entelos to supply it with computer systems, the companies announced on Wednesday.

The deal calls for Entelos to purchase Compaq’s AlphaServer systems, which run Tru64 UNIX, and ProLiant servers, running Linux. The systems will serve as the computational platforms for Entelos’ in silico  disease simulator PhysioLab, which runs large-scale target-validation experiments incorporating physiologic systems, including proteomic and genomic-level analysis, involved in disease progression.

Financial details of the agreement were not disclosed. 

Entelos, based in Menlo Park, Calif., currently uses Sun Solaris systems. The Compaq deal includes adapting the new equipment for in-house use in addition to recommending the systems to Entelos’ customers, said an Entelos spokeswoman. 

“Entelos is providing different ways to look at drug targets and candidates,” Daniel Joy, business development manager at Compaq's Life Sciences Group, told GenomeWeb . “The real benefit is to weed out the failures before they get to the clinical trial stage. [Compaq] is working with companies to improve the efficiency of the drug pipeline by applying high-performance computing solutions,” he added.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.